U.S. markets close in 2 hours 10 minutes
  • S&P 500

    4,224.60
    +58.15 (+1.40%)
     
  • Dow 30

    33,899.68
    +609.60 (+1.83%)
     
  • Nasdaq

    14,146.68
    +116.31 (+0.83%)
     
  • Russell 2000

    2,285.61
    +47.86 (+2.14%)
     
  • Crude Oil

    73.89
    +2.25 (+3.14%)
     
  • Gold

    1,783.10
    +14.10 (+0.80%)
     
  • Silver

    26.03
    +0.07 (+0.25%)
     
  • EUR/USD

    1.1920
    +0.0055 (+0.46%)
     
  • 10-Yr Bond

    1.4820
    +0.0320 (+2.21%)
     
  • GBP/USD

    1.3932
    +0.0123 (+0.89%)
     
  • USD/JPY

    110.2430
    +0.0930 (+0.08%)
     
  • BTC-USD

    32,198.73
    -2,472.93 (-7.13%)
     
  • CMC Crypto 200

    782.35
    -68.00 (-8.00%)
     
  • FTSE 100

    7,062.29
    +44.82 (+0.64%)
     
  • Nikkei 225

    28,010.93
    -953.15 (-3.29%)
     

Precigen Stock Surges On Positive AG019 Data for Chronic Treatment Of Type 1 Diabetes

·1 min read
  • Precigen Inc's (NASDAQ: PGEN) subsidiary Precigen ActoBio announced topline results from the Phase 1b/2a study evaluating AG019 ActoBiotics to treat recent-onset type 1 diabetes (T1D).

  • Results were presented at the Federation of Clinical Immunology Societies 2021.

  • Phase 1b AG019 monotherapy and the Phase 2a AG019 combination therapy met their primary endpoint.

  • Following a single 8-week treatment cycle of oral AG019 as monotherapy, 56% of adult patients showed stabilization or higher C-peptide levels during the first six months post-treatment initiation.

  • Results indicated the potential of oral AG019 monotherapy to preserve insulin production in recent-onset T1D through its capacity to reduce autoreactive T cells and increase the frequency of memory Tregs to induce antigen-specific immune modulation.

  • Following treatment with the combination of AG019 and Provention Bio Inc's (NASDAQ: PRVB) teplizumab, 70% of adult patients and 100% of adolescent patients showed stabilization or increase of C-peptide levels at six months post-treatment initiation, with overall stabilization of 79%.

  • AG019 was well tolerated and safe when administered to adults and adolescents either as monotherapy or in combination with teplizumab.

  • No serious adverse events were reported, and no AG019 treatment discontinuation occurred due to the adverse events.

  • Price Action: PGEN shares are up 38.3% at $9.67 during the premarket session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.